GlassScriptPhysician profile
Amina Baloch
NPI 1336698901
$3,543.60
in general payments reported to CMS, 2019-2025
27 companies · $729 in 2025
The $729 reported for 2025 was more than what 81% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $788 · 2022: $954 · 2023: $447 · 2024: $626 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $804.62 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $501.01 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $405.21 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $375.65 | 2021-2025 | Caplyta |
| Urovant Sciences INC | $146.08 | 2022 | |
| Abbvie INC. | $138.23 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $124.99 | 2024 | |
| Galderma Laboratories, L.P. | $121.50 | 2024 | |
| Sumitomo Pharma America, INC. | $108.94 | 2023-2025 | Gemtesa |
| Amgen INC. | $102.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $98.75 | 2021-2024 | Spravato, Invega Sustenna, Invega |
| Lundbeck LLC | $86.08 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $85.30 | 2023-2025 | Rexulti |
| Philips North America LLC | $64.13 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $59.42 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $52.11 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $45.61 | 2022 | |
| Avanir Pharmaceuticals, INC. | $40.16 | 2021 | |
| Lilly USA, LLC | $33.26 | 2024 | Mounjaro |
| Jazz Pharmaceuticals INC. | $25.91 | 2025 | |
| Abbott Laboratories | $24.26 | 2024 | Proclaim |
| Cmp Pharma, INC. | $20.45 | 2021 | |
| Indivior INC. | $18.04 | 2022 | |
| Exact Sciences Corporation | $17.10 | 2025 | The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $15.97 | 2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.15 | 2023 | Xifaxan |
| Viatris Specialty LLC | $13.46 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amina Baloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.